{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:10:39Z","timestamp":1793139039766,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ijrobp.2023.09.053","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T23:45:09Z","timestamp":1697672709000},"page":"998-1010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Safety of Ultrahypofractionated Pelvic Nodal Irradiation in the Definitive Management of Prostate Cancer: Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"118","author":[{"given":"Osama","family":"Mohamad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos","family":"Zamboglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedang","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Aebersold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Loblaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6477-6655","authenticated-orcid":false,"given":"Mohamed","family":"Shelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2023.09.053_bib0001","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0002","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijrobp.2015.09.020","article-title":"Outcome according to elective pelvic radiation therapy in patients with high-risk localized prostate cancer: A secondary analysis of the GETUG 12 phase 3 randomized trial","volume":"94","author":"Blanchard","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0003","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.22.02489","article-title":"Prostate-specific antigen level at the time of salvage therapy after radical prostatectomy for prostate cancer and the risk of death","volume":"41","author":"Tilki","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0004","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0005","unstructured":"Androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer. ClinicalTrials.gov identifier: NCT01368588. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01368588. Accessed June 24, 2023."},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0006","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0007","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1186\/s12885-020-07192-7","article-title":"Clinical impact of PSMA PET\/CT in primary prostate cancer compared to conventional nodal and distant staging: A retrospective single center study","volume":"20","author":"Donswijk","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0008","doi-asserted-by":"crossref","first-page":"134","DOI":"10.6004\/jnccn.2021.0008","article-title":"NCCN guidelines insights: Prostate cancer, version 1.2021","volume":"19","author":"Schaeffer","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0009","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.01097","article-title":"Hypofractionated radiation therapy for localized prostate cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline","volume":"36","author":"Morgan","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0010","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/13685538.2021.1948992","article-title":"The efficacy and tolerability of ultra-hypofractionated radiotherapy in low-intermediate risk prostate cancer patients: Single center experience","volume":"24","author":"Din\u00e7er","year":"2021","journal-title":"Aging Male"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0011","article-title":"Benefits of adopting hypofractionated radiotherapy as a standard of care in low-and middle-income countries","volume":"8","author":"Kraus","year":"2022","journal-title":"JCO Glob. Oncol."},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0012","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ijrobp.2020.01.010","article-title":"Diminishing returns from ultrahypofractionated radiation therapy for prostate cancer","volume":"107","author":"Vogelius","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0013","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0014","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/annonc\/mdw062","article-title":"Long-course oxaliplatin-based preoperative chemoradiation versus 5 \u00d7 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: Results of a randomized phase III study","volume":"27","author":"Bujko","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0015","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJM199704033361402","article-title":"Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer","volume":"336","author":"Cedermark","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0016","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0017","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","author":"Higgins","year":"2019","journal-title":"Cochrane handbook for systematic reviews of interventions. Cochrane Handbook for Systematic Reviews of Interventions"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0018","unstructured":"Study Quality Assessment Tools. NHLBI, NIH 2014. Available at:www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools. Accessed November 10, 2023."},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0019","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0020","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.brachy.2021.08.006","article-title":"Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer","volume":"20","author":"Gorovets","year":"2021","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0021","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijrobp.2018.11.011","article-title":"SABR in high-risk prostate cancer: Outcomes from 2 prospective clinical trials with and without elective nodal irradiation","volume":"104","author":"Alayed","year":"2019","journal-title":"Int J Radiat Oncol Biol. Phys."},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0022","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.radonc.2021.08.017","article-title":"Elective nodal ultra hypofractionated radiation for prostate cancer: Safety and efficacy from four prospective clinical trials","volume":"163","author":"Glicksman","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0023","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijrobp.2019.12.044","article-title":"Evaluating the tolerability of a simultaneous focal boost to the gross tumor in prostate SABR: A toxicity and quality-of-life comparison of two prospective trials","volume":"107","author":"Alayed","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0024","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.ijrobp.2015.02.046","article-title":"A phase 1\/2 trial of brief androgen suppression and stereotactic radiation therapy (FASTR) for high-risk prostate cancer","volume":"92","author":"Bauman","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0025","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.adro.2019.07.007","article-title":"A phase I\/II trial of fairly brief androgen suppression and stereotactic radiation therapy for high-risk prostate cancer (FASTR-2): Preliminary results and toxicity analysis","volume":"4","author":"Callan","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0026","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ijrobp.2021.10.137","article-title":"SABR for high-risk prostate cancer: A prospective multilevel MRI-based dose escalation trial","volume":"113","author":"Hannan","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0027","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ijrobp.2023.02.054","article-title":"A randomised feasibility trial of stereotactic prostate radiotherapy with or without elective nodal irradiation in high-risk localised prostate cancer (SPORT trial)","volume":"117","author":"Houlihan","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0028","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic resonance imaging-guided versus computed tomography-guided stereotactic body radiotherapy for prostate cancer: The MIRAGE randomized clinical trial","volume":"9","author":"Kishan","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0029","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.clon.2019.09.046","article-title":"A phase I\/II study of Stereotactic Hypofractionated Once-weekly Radiation Therapy (SHORT) for prostate cancer","volume":"32","author":"Mallick","year":"2020","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0030","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2022.05.050","article-title":"Acute and late adverse effects of prostate-only or pelvic stereotactic radiation therapy in prostate cancer: A comparative study","volume":"114","author":"Murthy","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0031","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.adro.2018.12.001","article-title":"Early tolerance outcomes of stereotactic hypofractionated accelerated radiation therapy concomitant with pelvic node irradiation in high-risk prostate cancer","volume":"4","author":"Pinitpatcharalert","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0032","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.3390\/cancers14143484","article-title":"A prospective study of stereotactic body radiotherapy (SBRT) with concomitant whole-pelvic radiotherapy (WPRT) for high-risk localized prostate cancer patients using 1.5 Tesla magnetic resonance guidance: The preliminary clinical outcome","volume":"14","author":"Poon","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0033","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.clon.2020.10.019","article-title":"Safety and efficacy of ultra-hypofractionation in node-positive prostate cancer","volume":"33","author":"Telkhade","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0034","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ijrobp.2018.07.2005","article-title":"Phase 1-2 study of stereotactic ablative radiotherapy including regional lymph node irradiation in patients with high-risk prostate cancer (SATURN): Early toxicity and quality of life","volume":"102","author":"Musunuru","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0035","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.radonc.2021.05.024","article-title":"Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, toxicity and quality of life","volume":"161","author":"Musunuru","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0036","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijrobp.2008.08.002","article-title":"RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer","volume":"74","author":"Lawton","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0037","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.ijrobp.2015.03.021","article-title":"Consensus guidelines and contouring atlas for pelvic node delineation in prostate and pelvic node intensity modulated radiation therapy","volume":"92","author":"Harris","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0038","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijrobp.2020.08.034","article-title":"NRG oncology updated international consensus atlas on pelvic lymph node volumes for intact and postoperative prostate cancer","volume":"109","author":"Hall","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0039","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.ijrobp.2015.08.006","article-title":"In regard to Bauman et al","volume":"93","author":"Kishan","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0040","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ijrobp.2021.01.016","article-title":"Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) consortium: Analysis of 344 prospectively treated patients","volume":"110","author":"van Dams","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0041","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034623","article-title":"Study protocol of a randomised controlled trial of prostate radiotherapy in high-risk and node-positive disease comparing moderate and extreme hypofractionation (PRIME trial)","volume":"10","author":"Murthy","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0042","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1186\/s12885-020-07490-0","article-title":"Is hypofractionated whole pelvis radiotherapy (WPRT) as well tolerated as conventionally fractionated WPRT in prostate cancer patients? The HOPE trial","volume":"20","author":"Mendez","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0043","unstructured":"SBRT versus conventional fractionation with HDR boost for prostate cancer. ClinicalTrials.gov identifier: NCT01368588. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01368588. Accessed June 24, 2023."},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0044","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.ijrobp.2022.04.008","article-title":"Meta-analysis of elective pelvic nodal irradiation using moderate hypofractionation for high-risk prostate cancer","volume":"113","author":"Viani","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0045","doi-asserted-by":"crossref","first-page":"e514","DOI":"10.1016\/j.prro.2020.06.012","article-title":"Long-term results of moderate hypofractionation to prostate and pelvic nodes plus androgen suppression in high-risk prostate cancer","volume":"10","author":"Faria","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0046","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/j.clon.2021.08.010","article-title":"Moderately hypofractionated radiotherapy and androgen deprivation therapy for high-risk localised prostate cancer: Predictors of long-term biochemical control and toxicity","volume":"34","author":"Maulik","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0047","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijrobp.2010.09.018","article-title":"Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer","volume":"82","author":"Adkison","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0048","doi-asserted-by":"crossref","first-page":"308","DOI":"10.21037\/tau.2017.12.37","article-title":"Image-guided radiotherapy for prostate cancer","volume":"7","author":"Dang","year":"2018","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0049","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.canrad.2020.06.033","article-title":"Evaluation of margins in pelvic lymph nodes and prostate radiotherapy and the impact of bladder and rectum on prostate position","volume":"25","author":"Marnouche","year":"2021","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2478\/raon-2023-0004","article-title":"Effects of gold fiducial marker implantation on tumor control and toxicity in external beam radiotherapy of prostate cancer","volume":"57","author":"Moll","year":"2023","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0051","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20181001","article-title":"Stereotactic body radiotherapy to the prostate and pelvic lymph nodes: A detailed dosimetric analysis of a phase II prospective trial","volume":"92","author":"Kishan","year":"2019","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0052","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/acm2.13399","article-title":"Prospects for daily online adaptive radiotherapy via ethos for prostate cancer patients without nodal involvement using unedited CBCT auto-segmentation","volume":"22","author":"Moazzezi","year":"2021","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0053","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.radonc.2021.12.013","article-title":"Online adaptive radiotherapy potentially reduces toxicity for high-risk prostate cancer treatment","volume":"167","author":"Christiansen","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0054","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1186\/s12885-021-08281-x","article-title":"Magnetic Resonance Imaging-Guided Stereotactic Body Radiotherapy for Prostate Cancer (MIRAGE): A phase III randomized trial","volume":"21","author":"Ma","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2023.09.053_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/S0167-8140(19)30566-3","article-title":"PV-0146 RTOG versus CTCAE score: reporting toxicity of HDR brachytherapy Monotherapy for prostate cancer","volume":"133","author":"Jolicoeur","year":"2019","journal-title":"Radiotherapy and Oncology"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623080069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623080069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:10:24Z","timestamp":1759745424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301623080069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0360301623080069"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.09.053","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of Ultrahypofractionated Pelvic Nodal Irradiation in the Definitive Management of Prostate Cancer: Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.09.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}